openPR Logo
Press release

Frontier Pharma: Alzheimers Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD

06-08-2017 07:22 PM CET | Health & Medicine

Press release from: Pharmaceutical Market Reports - MRH

Market Research HUB

Market Research HUB

Alzheimer’s disease (AD), the most common form of dementia, is a progressive, neurodegenerative and currently incurable disease characterized by loss of memory and other mental abilities. It has a devastating impact on independence and quality of life, with patients requiring full-time care in the later disease stages. In addition to cognitive impairment, AD is associated with behavioral and psychological changes, which often represent the greatest challenges for patients and caregivers.

Request Free Sample Report -

The prevalence of AD is escalating rapidly, largely owing to aging populations, as advancing age is the most important epidemiological risk factor for the disease. This will amplify the already substantial societal and economic costs of the disease over the coming years. This has led to high levels of R&D investment over the past two decades, but clinical trial failure rates within the indication are extremely high and treatment options remain limited. There are no disease-modifying therapies for AD, and current approaches can only temporarily slow the worsening of symptoms.

The report focuses on AD alongside four key associated behavioral and psychological indications: anxiety, depression, psychosis and insomnia. These four conditions are highly prevalent in AD and contribute substantially to the disease burden.


Unmet need is extremely high in AD, with behavioral and psychological complications contributing significantly to the disease burden

- What are the most important etiological risk factors and pathophysiological processes implicated in AD?
- What is the current treatment algorithm?
- How common are anxiety, depression, psychosis and insomnia in AD?

The AD pipeline is large and contains a very high proportion of first-in-class product innovation

- Which molecule types and molecular targets are most prominent across AD and its associated indications?
- What are the connections, in terms of first-in-class innovation, between AD and its associated indications?
- Which first-in-class targets are most promising?
- How does the level of first-in-class innovation differ between products in development for anxiety, depression, psychosis and insomnia?
- How does first-in-class target diversity differ by stage of development and molecular target class?

The deals landscape is active and dominated by G-protein coupled receptor (GPCR)-targeting products

- Which indications attract the highest deal values?
- How has deal activity fluctuated over the past decade?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Browse Full Report with TOC -

Reasons to buy

This report will allow you to -

- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, diagnosis and treatment options.
- Identify leading products and key unmet needs within the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for AD, anxiety, depression, psychosis and insomnia. Promising early-stage first-in-class targets are reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Executive Summary 6
2.1 Limited Treatment Options despite Large Market Opportunity 6
2.2 Exceptionally High Level of First-in-Class Innovation within Alzheimer’s Disease Pipeline 6
2.3 Active Deals Landscape Dominated by GPCR-Targeting Products 6

3 The Case for Innovation 7
3.1 Growing Opportunities for Biologic Products 8
3.2 Diversification of Molecular Targets 8
3.3 Innovative First-in-Class Product Developments Remain Attractive 9
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 9
3.5 Sustained Innovation in Alzheimer’s Disease 10
3.6 GBI Research Report Guidance 10

4 Clinical and Commercial Landscape 12
4.1 Disease Overview 12
4.2 Classification of Dementia and Mild Cognitive Impairment 12
4.3 Symptoms, Disease Staging and Prognosis 13
4.4 Diagnosis 14
4.4.1 Mini Mental State Exam 15
4.4.2 Alzheimer’s Disease Assessment Scale - Cognitive 15
4.4.3 Alzheimer’s Disease Co-operative Study - Activities of Daily Living Inventory 16
4.4.4 Imaging Techniques 16
4.4.5 Lumbar Puncture 17
4.4.6 Blood Tests 17
4.5 Epidemiology 17
4.6 Etiology and Pathophysiology 17
4.6.1 Etiological Risk Factors 17
4.6.2 Pathophysiology 18
4.7 Management and Treatment of Alzheimer’s Disease 21
4.7.1 Pharmacological Intervention 21
4.7.2 Non-pharmacological Intervention 22
4.8 Overview of Marketed Products 23
4.9 Indications Associated with Alzheimer’s Disease 26
4.9.1 Anxiety 26
4.9.2 Depression 27
4.9.3 Psychosis 28
4.9.4 Insomnia 29

5 Assessment of Pipeline Product Innovation 30

Make an Enquiry -

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email :
Website :
Read Industry News at -

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Frontier Pharma: Alzheimers Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD here

News-ID: 570666 • Views: 205

More Releases from Pharmaceutical Market Reports - MRH

Global Active Pharmaceutical Ingredients Market Size, Growth, Share, Trends and …
Market Research Hub includes new market research report "Global Active Pharmaceutical Ingredients Market Research Report 2017-2022 by Players, Regions, Product Types & Applications" to its huge collection of research reports. The global Active Pharmaceutical Ingredients market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Request Free Sample Report -
Global and Chinese Carfentanil Expedient Market Outlook and Profitable Forecasts …
The carfentanil market is witnessing huge developments in the veterinary and other chemical research sectors. Looking into this development, a new report has been added to the vast online repository of Market Research Hub (MRH), with the title ‘’Global and Chinese Carfentanil Market Outlook 2017-2022‘’. The study offers a precise evaluation of the most positive business factors such as biggest players and regions; as well as a prospective forecast till
Global Propofol Sales Market Size, Share, Growth, Trends and Forecast
According to the report "Global Propofol Sales Market Report 2017" added by Market Research HUB, the global Propofol market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate
Global Mammalian Cell Culture Sales Market Size, Share, Trends and Forecast
According to the report "Global Mammalian Cell Culture Sales Market Report 2017" added by Market Research HUB, the global Mammalian Cell Culture market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market

All 5 Releases

More Releases for Disease

Infectious Disease Diagnostic Market
Infectious disease diagnostics involves identifying the presence of foreign antigen/organism using diagnostic tools such as kits. Most of the standard diagnostic test kits currently available are for bacterial infections and sexually transmitted diseases. However, in future these diagnostic tests are expected to be replaced by molecular techniques. The global infectious disease diagnostic market is expected to witness significant growth during the forecast period due to increasing prevalence of infectious diseases, increased
Crohns Disease Treatment Market
Crohn’s disease is a chronic inflammatory bowel syndrome that causes inflammation in the gastrointestinal tract. Inflammation can take place anywhere between mouth to anus. It commonly affects end of small intestine (Ileum) and beginning of the colon. Common symptoms of Crohn’s disease from mild to severe intensity include abdominal pain, frequent diarrhea, reduced appetite, and fever. Sometimes rectal bleeding is also observed due to fissures from inflammation at anal canal.
Peyronie’s Disease Treatment Market
Peyronie's disease (PD) is condition wherein the penis is curved or bent due to development of plaque or a fibrous scar tissue inside the penis. This condition can cause painful erections and the penis gets bent while it is erected. The bent is towards the side where plaque is being formed i.e. either downwards or upwards. The condition is identified by a major bend or pain. In a few people
Global Gaucher Disease Treatment Market
Gaucher disease is recessive gene dominance disorder with massive clinical heterogeneity. Symptoms of the disease include painless splenomegaly, anemia, or thrombocytopenia, chronic fatigue, hepatomegaly, bone pain, and pathologic fractures. The disease also contributes to easy incidence of bruising and bleeding through the nose. Manifested in three sub-types, the disease results from the deficiency of the enzyme glucocerebrosidase. It is the most common lysosomal storage disorder and has an incidence of
Otava Alzheimer’s Disease Targeted Libraries
Alzheimer’s disease (AD) is a devastating and always fatal neurodegenerative disorder characterized by progressive impairment of cognitive function and emotional disturbances. Currently, more than 25 million people worldwide live with AD. But there is no cure for AD and no treatment to reverse its progression, there are medicines available that can help treat symptoms in some people with this disease. Intensive scientific research around the world brings us closer to
Cardiovascular Disease Prevention
Reduce Your Risk of Cardiovascular Disease… Useful information about how you can lower your blood pressure, lower cholesterol, and decrease your risk of heart disease. One person dies every 30 seconds from heart disease. That's over 2,600 people every single day!! Cardiovascular disease refers to any disorder in any of the various parts of your cardiovascular system, which includes your heart and blood vessels. The heart is the